Cargando…
Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
Triple negative breast cancer (TNBC) is highly immunogenic and high levels of tumor infiltrating lymphocytes (TILs) have been associated with a better prognosis and higher probability to achieve pathological complete response. Here, we explore the potential role of stromal TILs level and composition...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694133/ https://www.ncbi.nlm.nih.gov/pubmed/38044375 http://dx.doi.org/10.1038/s41598-023-48300-4 |
_version_ | 1785153306124877824 |
---|---|
author | Huertas-Caro, Carlos A. Ramírez, Mayra A. Rey-Vargas, Laura Bejarano-Rivera, Lina María Ballen, Diego Felipe Nuñez, Marcela Mejía, Juan Carlos Sua-Villegas, Luz Fernanda Cock-Rada, Alicia Zabaleta, Jovanny Fejerman, Laura Sanabria-Salas, María Carolina Serrano-Gomez, Silvia J. |
author_facet | Huertas-Caro, Carlos A. Ramírez, Mayra A. Rey-Vargas, Laura Bejarano-Rivera, Lina María Ballen, Diego Felipe Nuñez, Marcela Mejía, Juan Carlos Sua-Villegas, Luz Fernanda Cock-Rada, Alicia Zabaleta, Jovanny Fejerman, Laura Sanabria-Salas, María Carolina Serrano-Gomez, Silvia J. |
author_sort | Huertas-Caro, Carlos A. |
collection | PubMed |
description | Triple negative breast cancer (TNBC) is highly immunogenic and high levels of tumor infiltrating lymphocytes (TILs) have been associated with a better prognosis and higher probability to achieve pathological complete response. Here, we explore the potential role of stromal TILs level and composition as a prognostic and predictive biomarker in TNBC. 195 Tumor biospecimens from patients diagnosed with TNBC were included. Stromal TILs (sTILs), positive CD4/CD8 cells were evaluated. Differences in clinic-pathological characteristics according to immune infiltration were assessed. The predictive and prognostic value of immune infiltration was analyzed by multivariate models. Higher immune infiltration was observed in patients with favorable clinical–pathological features. Survival analysis showed that longer overall survival times were observed in patients with a higher infiltration of sTILs (p = 0.00043), CD4 + (p = 0.0074) and CD8 + (p = 0.008). In the multivariate analysis, low levels of sTILs were found to be associated with a higher mortality hazard (HR: 1.59, 95% CI 1.01–2.48). CD4 and CD8 immune infiltration were associated with higher odds for pathological complete response (OR: 1.20, 95% CI 1.00–1.46, OR: 1.28, 1.02–1.65, respectively). Our results suggest that immune infiltration could be used as a prognostic marker for overall survival in TNBC patients. |
format | Online Article Text |
id | pubmed-10694133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106941332023-12-05 Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer Huertas-Caro, Carlos A. Ramírez, Mayra A. Rey-Vargas, Laura Bejarano-Rivera, Lina María Ballen, Diego Felipe Nuñez, Marcela Mejía, Juan Carlos Sua-Villegas, Luz Fernanda Cock-Rada, Alicia Zabaleta, Jovanny Fejerman, Laura Sanabria-Salas, María Carolina Serrano-Gomez, Silvia J. Sci Rep Article Triple negative breast cancer (TNBC) is highly immunogenic and high levels of tumor infiltrating lymphocytes (TILs) have been associated with a better prognosis and higher probability to achieve pathological complete response. Here, we explore the potential role of stromal TILs level and composition as a prognostic and predictive biomarker in TNBC. 195 Tumor biospecimens from patients diagnosed with TNBC were included. Stromal TILs (sTILs), positive CD4/CD8 cells were evaluated. Differences in clinic-pathological characteristics according to immune infiltration were assessed. The predictive and prognostic value of immune infiltration was analyzed by multivariate models. Higher immune infiltration was observed in patients with favorable clinical–pathological features. Survival analysis showed that longer overall survival times were observed in patients with a higher infiltration of sTILs (p = 0.00043), CD4 + (p = 0.0074) and CD8 + (p = 0.008). In the multivariate analysis, low levels of sTILs were found to be associated with a higher mortality hazard (HR: 1.59, 95% CI 1.01–2.48). CD4 and CD8 immune infiltration were associated with higher odds for pathological complete response (OR: 1.20, 95% CI 1.00–1.46, OR: 1.28, 1.02–1.65, respectively). Our results suggest that immune infiltration could be used as a prognostic marker for overall survival in TNBC patients. Nature Publishing Group UK 2023-12-03 /pmc/articles/PMC10694133/ /pubmed/38044375 http://dx.doi.org/10.1038/s41598-023-48300-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Huertas-Caro, Carlos A. Ramírez, Mayra A. Rey-Vargas, Laura Bejarano-Rivera, Lina María Ballen, Diego Felipe Nuñez, Marcela Mejía, Juan Carlos Sua-Villegas, Luz Fernanda Cock-Rada, Alicia Zabaleta, Jovanny Fejerman, Laura Sanabria-Salas, María Carolina Serrano-Gomez, Silvia J. Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer |
title | Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer |
title_full | Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer |
title_fullStr | Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer |
title_full_unstemmed | Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer |
title_short | Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer |
title_sort | tumor infiltrating lymphocytes (tils) are a prognosis biomarker in colombian patients with triple negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694133/ https://www.ncbi.nlm.nih.gov/pubmed/38044375 http://dx.doi.org/10.1038/s41598-023-48300-4 |
work_keys_str_mv | AT huertascarocarlosa tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT ramirezmayraa tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT reyvargaslaura tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT bejaranoriveralinamaria tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT ballendiegofelipe tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT nunezmarcela tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT mejiajuancarlos tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT suavillegasluzfernanda tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT cockradaalicia tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT zabaletajovanny tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT fejermanlaura tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT sanabriasalasmariacarolina tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer AT serranogomezsilviaj tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer |